Genfit S.A. (GNFT)
Stock Price:
$5.44 USD
-0.08 (-1.45%)
Updated Jul 2, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
211.29M |
| Revenue (ttm) |
46.02M |
| Net Income (ttm) |
-73.20M |
| Shares Out |
38.84M |
| EPS (ttm) |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Jul 2, 2020 |
| Last Price |
$5.44 |
| Previous Close |
$5.52 |
| Change ($) |
-0.08 |
| Change (%) |
-1.45% |
| Day's Open |
5.59 |
| Day's Range |
5.38 - 5.58 |
| Day's Volume |
22,817 |
| 52-Week Range |
5.15 - 22.48 |
More Stats
| Market Cap |
211.29M |
| Enterprise Value |
106.65M |
| Earnings Date (est) |
Sep 30, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
38.84M |
| Float |
36.92M |
| EPS (basic) |
n/a |
| EPS (diluted) |
n/a |
| FCF / Share |
-1.47 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
68,773 |
| Short Ratio |
0.33 |
| Short % of Float |
n/a |
| Beta |
0.88 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
4.59 |
| PB Ratio |
2.42 |
| Revenue |
46.02M |
| Operating Income |
-64.98M |
| Net Income |
-73.20M |
| Free Cash Flow |
-53.03M |
| Net Cash |
104.64M |
| Net Cash / Share |
2.70 |
| Gross Margin |
100.00% |
| Operating Margin |
-141.19% |
| Profit Margin |
-159.00% |
| FCF Margin |
-115.21% |
| ROA |
-13.87% |
| ROE |
-124.08% |
| ROIC |
-32.50% |
Key stats in USD, based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (12)
| Buy |
3 |
| Overweight |
0 |
| Hold |
7 |
| Underweight |
2 |
| Sell |
0 |
Analyst Consensus: Overweight
Price Target
$11.40*
(109.56% upside)
Low
5.41
Current: 5.44
High
20.00
Target: 11.40
*Average 12-month USD price target from 12 stock analysts.
Financial Performance
Financial numbers in millions EUR.
Financial Overview
| Year | 2019 | 2018 | 2017 |
|---|
| Revenue | 40.96 | 7.49 | 6.86 |
| Revenue Growth | 446.58% | 9.31% | - |
| Gross Profit | 40.96 | 7.49 | 6.86 |
| Operating Income | -57.83 | -69.49 | -56.69 |
| Net Income | -65.14 | -79.52 | -55.73 |
| Shares Outstanding | 36.18 | 36.18 | - |
| Earnings Per Share | -1.76 | -2.55 | -1.79 |
| Operating Cash Flow | -47.68 | -56.08 | -49.86 |
| Capital Expenditures | 0.49 | -2.94 | -2.79 |
| Free Cash Flow | -47.19 | -59.02 | -52.64 |
| Cash & Equivalents | 277 | 207 | 274 |
| Total Debt | 184 | 170 | 165 |
| Net Cash / Debt | 93.13 | 37.65 | 109 |
| Assets | 310 | 229 | 293 |
| Liabilities | 226 | 209 | 192 |
| Book Value | 84.07 | 20.94 | 101 |
Numbers in millions EUR, except per-share numbers.
Company Details
| Full Name |
Genfit S.A. |
| Country |
France |
| Employees |
194 |
| CEO |
Pascal Prigent |
Stock Information
| Ticker Symbol |
GNFT |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: GNFT |
Description
Genfit SA, a biopharmaceutical company, develops therapeutic and diagnostic solutions for metabolic, inflammatory, autoimmune, and fibrotic diseases affecting primarily the liver and gastroenterology. The company's lead products include Elafibranor, which is in pivotal Phase III clinical trials for the treatment of nonalcoholic steatohepatitis (NASH), as well as completed Phase II clinical trial to treat patients with primary biliary cholangitis; and Nitazoxanide that is in Phase II proof-of-concept clinical trial for the treatment of NASH-induced significant or severe fibrosis. It is also developing in-vitro diagnostic tests for the identification of patients with NASH; NIS4 for identifying patients with NASH and fibrosis; and TGFTX1 preclinical program for treating psoriasis or respiratory conditions, such as neutrophilic asthma, chronic obstructive pulmonary disease (COPD), and the asthma-COPD overlap syndrome. Genfit SA was founded in 1999 and is headquartered in Loos, France.